Pemetrexed ditromethamine formulations for which Dr Reddy’s and Pfizer’s Hospira are seeking approval through the US hybrid 505(b)(2) regulatory pathway infringe the sole listed patent protecting Eli Lilly’s Alimta (pemetrexed disodium) lung-cancer treatment under the doctrine of equivalents, the US Court of Appeals for the Federal Circuit has found.
Reddy’s and Hospira had appealed against infringement decisions handed down against them last year by a district court in Lilly’s...






